Advanced Biomed（ADVB）株式概要投資持株会社であるアドバンスト・バイオメッド社は、台湾で精密腫瘍学の検出、診断、治療のためのマイクロ流体バイオチップ技術の研究開発に従事している。 詳細ADVB ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性3/6配当金0/6報酬株価収益率（ 1.7 x） US市場（ 19.2 x）を下回っています。今年は黒字化を達成 リスク分析高いレベルの非現金収入 過去1年間で株主の希薄化は大幅に進んだ US市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( $0 )+1 さらなるリスクすべてのリスクチェックを見るADVB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW489,735 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG489,735 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$5.03該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m5m2016201920222025202620282031Revenue US$1.0Earnings US$0AdvancedSet Fair ValueView all narrativesAdvanced Biomed Inc. 競合他社Meihua International Medical TechnologiesSymbol: OTCPK:MHUA.FMarket cap: US$7.5mMedinotecSymbol: OTCPK:MDNCMarket cap: US$58.7mXtant Medical HoldingsSymbol: NYSEAM:XTNTMarket cap: US$63.1mAcme UnitedSymbol: NYSEAM:ACUMarket cap: US$181.2m価格と性能株価の高値、安値、推移の概要Advanced Biomed過去の株価現在の株価US$5.0352週高値US$15.2052週安値US$3.61ベータ01ヶ月の変化-1.37%3ヶ月変化0.60%1年変化-63.38%3年間の変化n/a5年間の変化n/aIPOからの変化-93.11%最新ニュースお知らせ • Jun 05Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026, at 10:00 Taipei Standard Time. Location: no. 689-85 xiaodong road, yongkang district, tainan TaiwanNew Risk • May 18New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 212% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (212% accrual ratio). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.19m market cap).New Risk • May 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 35%After last week's 35% share price gain to US$7.20, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 24x in the Medical Equipment industry in the US. Total loss to shareholders of 66% over the past year.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 36%After last week's 36% share price gain to US$6.47, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Medical Equipment industry in the US. Total loss to shareholders of 83% over the past year.New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$6.03m market cap). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).最新情報をもっと見るRecent updatesお知らせ • Jun 05Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026, at 10:00 Taipei Standard Time. Location: no. 689-85 xiaodong road, yongkang district, tainan TaiwanNew Risk • May 18New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 212% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (212% accrual ratio). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.19m market cap).New Risk • May 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 35%After last week's 35% share price gain to US$7.20, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 24x in the Medical Equipment industry in the US. Total loss to shareholders of 66% over the past year.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 36%After last week's 36% share price gain to US$6.47, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Medical Equipment industry in the US. Total loss to shareholders of 83% over the past year.New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$6.03m market cap). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 43%After last week's 43% share price gain to US$6.52, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 27x in the Medical Equipment industry in the US. Total loss to shareholders of 82% over the past year.Board Change • Feb 14High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman Yi Lu is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 31Wei Ha Hui acquired Advanced Biomed HK Limited from Advanced Biomed Inc. (NasdaqCM:ADVB) for $0.02 million.Wei Ha Hui entered into an agreement to acquire Advanced Biomed HK Limited from Advanced Biomed Inc. (NasdaqCM:ADVB) for $0.02 million on December 23, 2025. A cash consideration of $0.02 million will be paid by Wei Ha Hui. As part of consideration, $0.02 million is paid towards common equity of Advanced Biomed HK Limited. All intellectual property owned by Advanced Biomed HK, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of Advanced Biomed HK, was transferred to Wei Ha Hui at the closing of this transaction on December 23, 2025. The transaction has been unanimously approved by the Advanced Biomed Inc. board. Wei Ha Hui completed the acquisition of Advanced Biomed HK Limited from Advanced Biomed Inc. (NasdaqCM:ADVB) on December 23, 2025.お知らせ • Nov 15Advanced Biomed Inc. announced delayed 10-Q filingOn 11/14/2025, Advanced Biomed Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 01Advanced Biomed Inc. announced delayed annual 10-K filingOn 09/30/2025, Advanced Biomed Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 19Advanced Biomed Inc. Announces Launch of A+PerfusC™? - Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug DiscoveryAdvanced Biomed Inc. announced the launch of its A+PerfusC™? system, a compact, all-in-one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. The A+PerfusC®? platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real-time observation. The system supports up to 12 days of continuous, hands-free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability. The system is characterized and proved by: 8 independent channel/patient source per plate; 600 tumor spheroids per row for one patient; 4,800 tumor spheroids per plate; Easy to transfer into 96 or 384 well plate for high-throughput drug screening; Easy to mount on microscopy platforms; Expandable- control platform supporting up to four incubators. A+PerfusCTM system and its 3D culture plate (consumable) have passed internal testing and validation with design finalized. Currently the Company is advancing its mass-production development. Its commercialization can be achieved following mass-production development finalized and quality control standards established. Potential applications include personalized oncology research, invitro drug screening, regenerative medicine, organoid studies, and stem cell research. According to Mordor Intelligence, the global 3D cell culture market was valued at USD 2.32 billion in 2025 and is projected to exceed USD 4.71 billion by 2030, representing a compound annual growth rate of over 15.6%.New Risk • Aug 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.25m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.25m market cap).お知らせ • Jul 25Advanced Biomed Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn July 18, 2025, Advanced Biomed Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 32 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol “ADVB.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until January 14, 2026 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period. If the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for an additional 180 calendar day compliance period, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market (except for the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency during the second compliance period, including, if necessary, by effecting a reverse stock split. The Company intends to monitor the closing bid price of its common stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement within the compliance period.お知らせ • Jun 07Advanced Biomed Inc. announced that it expects to receive $25 million in funding from Helena Global Investment Opportunities 1 Ltd.Advanced Biomed Inc. announced that it has entered into an equity line purchase agreement to issue common shares for gross proceeds of $25,000,000 on June 6, 2025. The equity line agreement shall be terminated automatically on the earliest of the first day of the month next following the 24-month anniversary of the date hereof or the date on which the investor shall have made payment of advances pursuant to this agreement for common stock equal to the commitment amount. The transaction includes participation from new investor, Helena Global Investment Opportunities 1 Ltd.New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.8m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$25.1m market cap).New Risk • Apr 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.4m free cash flow). Earnings have declined by 1.9% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$41.1m market cap).お知らせ • Mar 07Advanced Biomed Inc. has completed an IPO in the amount of $6.56 million.Advanced Biomed Inc. has completed an IPO in the amount of $6.56 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,640,000 Price\Range: $4 Discount Per Security: $0.3Board Change • Mar 06No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Secretary & Director Hung Pau is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.株主還元ADVBUS Medical EquipmentUS 市場7D-2.5%-1.6%-2.0%1Y-63.4%-18.4%17.4%株主還元を見る業界別リターン: ADVB過去 1 年間で-18.4 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: ADVBは、過去 1 年間で17.4 % のリターンを上げたUS市場を下回りました。価格変動Is ADVB's price volatile compared to industry and market?ADVB volatilityADVB Average Weekly Movement17.2%Medical Equipment Industry Average Movement8.4%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.2%安定した株価: ADVBの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ADVBの weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201431Xiaomin Chenwww.advanbiomed.com投資持株会社であるアドバンスト・バイオメッド社は、台湾で精密腫瘍学の検出、診断、治療のためのマイクロ流体バイオチップ技術の研究開発に従事している。同社の装置には、希釈血液サンプルの前濃縮を可能にする自動サンプル前処理システムA+Pre、腫瘍患者の凝固亢進状態サンプルの検出問題を解決する希少細胞装置AC-1000、循環腫瘍細胞（CTC）単一細胞捕捉装置A+SCDrop、AC-1000製品の免疫染色／分析用免疫染色チップ搭載分析装置A+CellScanなどがある。同社はまた、A+Pre、AC-1000 CTC濃縮、A+CellScanチップなどのマイクロ流体バイオチップを提供し、がん患者にアッセイ製品やサービスを提供している。さらに、免疫発色性キットには、EpCAM、CK（pan）、CD45、CD14抗体の免疫発色性により上皮性循環腫瘍細胞を同定するA+CTCEキット、Vimentin、CD45、CD14抗体の免疫発色性により間葉性循環腫瘍細胞を同定するA+CTCMキットがある；A+EMTは、細胞表面のVimentin、CD45、CD14抗体の免疫発色性に基づき、上皮間葉系循環腫瘍細胞を同定するためのキットであり、A+CMは、PD-L1、CD45、CD14抗体の免疫発色性に基づき、腫瘍関連マクロファージを同定するためのキットである。さらに、肺がんの早期スクリーニングを目的としたA+LCGuardを開発中である。さらに、中華人民共和国で診療所を設立・運営している。同社は2014年に設立され、ニューヨーク州ニューヨークに本社を置いている。もっと見るAdvanced Biomed Inc. 基礎のまとめAdvanced Biomed の収益と売上を時価総額と比較するとどうか。ADVB 基礎統計学時価総額US$8.31m収益（TTM）US$4.76m売上高(TTM)n/a1.7xPER（株価収益率0.0xP/SレシオADVB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ADVB 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用-US$4.76m収益US$4.76m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）2.88グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率7.4%ADVB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/19 19:13終値2026/07/17 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Advanced Biomed Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 05Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026, at 10:00 Taipei Standard Time. Location: no. 689-85 xiaodong road, yongkang district, tainan Taiwan
New Risk • May 18New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 212% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (212% accrual ratio). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.19m market cap).
New Risk • May 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 35%After last week's 35% share price gain to US$7.20, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 24x in the Medical Equipment industry in the US. Total loss to shareholders of 66% over the past year.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 36%After last week's 36% share price gain to US$6.47, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Medical Equipment industry in the US. Total loss to shareholders of 83% over the past year.
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$6.03m market cap). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).
お知らせ • Jun 05Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026Advanced Biomed Inc., Annual General Meeting, Jun 30, 2026, at 10:00 Taipei Standard Time. Location: no. 689-85 xiaodong road, yongkang district, tainan Taiwan
New Risk • May 18New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 212% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (212% accrual ratio). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.19m market cap).
New Risk • May 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 35%After last week's 35% share price gain to US$7.20, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 24x in the Medical Equipment industry in the US. Total loss to shareholders of 66% over the past year.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 36%After last week's 36% share price gain to US$6.47, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Medical Equipment industry in the US. Total loss to shareholders of 83% over the past year.
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$6.03m market cap). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 43%After last week's 43% share price gain to US$6.52, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 27x in the Medical Equipment industry in the US. Total loss to shareholders of 82% over the past year.
Board Change • Feb 14High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman Yi Lu is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 31Wei Ha Hui acquired Advanced Biomed HK Limited from Advanced Biomed Inc. (NasdaqCM:ADVB) for $0.02 million.Wei Ha Hui entered into an agreement to acquire Advanced Biomed HK Limited from Advanced Biomed Inc. (NasdaqCM:ADVB) for $0.02 million on December 23, 2025. A cash consideration of $0.02 million will be paid by Wei Ha Hui. As part of consideration, $0.02 million is paid towards common equity of Advanced Biomed HK Limited. All intellectual property owned by Advanced Biomed HK, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of Advanced Biomed HK, was transferred to Wei Ha Hui at the closing of this transaction on December 23, 2025. The transaction has been unanimously approved by the Advanced Biomed Inc. board. Wei Ha Hui completed the acquisition of Advanced Biomed HK Limited from Advanced Biomed Inc. (NasdaqCM:ADVB) on December 23, 2025.
お知らせ • Nov 15Advanced Biomed Inc. announced delayed 10-Q filingOn 11/14/2025, Advanced Biomed Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 01Advanced Biomed Inc. announced delayed annual 10-K filingOn 09/30/2025, Advanced Biomed Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 19Advanced Biomed Inc. Announces Launch of A+PerfusC™? - Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug DiscoveryAdvanced Biomed Inc. announced the launch of its A+PerfusC™? system, a compact, all-in-one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. The A+PerfusC®? platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real-time observation. The system supports up to 12 days of continuous, hands-free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability. The system is characterized and proved by: 8 independent channel/patient source per plate; 600 tumor spheroids per row for one patient; 4,800 tumor spheroids per plate; Easy to transfer into 96 or 384 well plate for high-throughput drug screening; Easy to mount on microscopy platforms; Expandable- control platform supporting up to four incubators. A+PerfusCTM system and its 3D culture plate (consumable) have passed internal testing and validation with design finalized. Currently the Company is advancing its mass-production development. Its commercialization can be achieved following mass-production development finalized and quality control standards established. Potential applications include personalized oncology research, invitro drug screening, regenerative medicine, organoid studies, and stem cell research. According to Mordor Intelligence, the global 3D cell culture market was valued at USD 2.32 billion in 2025 and is projected to exceed USD 4.71 billion by 2030, representing a compound annual growth rate of over 15.6%.
New Risk • Aug 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.25m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.25m market cap).
お知らせ • Jul 25Advanced Biomed Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn July 18, 2025, Advanced Biomed Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 32 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol “ADVB.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until January 14, 2026 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period. If the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for an additional 180 calendar day compliance period, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market (except for the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency during the second compliance period, including, if necessary, by effecting a reverse stock split. The Company intends to monitor the closing bid price of its common stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement within the compliance period.
お知らせ • Jun 07Advanced Biomed Inc. announced that it expects to receive $25 million in funding from Helena Global Investment Opportunities 1 Ltd.Advanced Biomed Inc. announced that it has entered into an equity line purchase agreement to issue common shares for gross proceeds of $25,000,000 on June 6, 2025. The equity line agreement shall be terminated automatically on the earliest of the first day of the month next following the 24-month anniversary of the date hereof or the date on which the investor shall have made payment of advances pursuant to this agreement for common stock equal to the commitment amount. The transaction includes participation from new investor, Helena Global Investment Opportunities 1 Ltd.
New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.8m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$25.1m market cap).
New Risk • Apr 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.4m free cash flow). Earnings have declined by 1.9% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$41.1m market cap).
お知らせ • Mar 07Advanced Biomed Inc. has completed an IPO in the amount of $6.56 million.Advanced Biomed Inc. has completed an IPO in the amount of $6.56 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,640,000 Price\Range: $4 Discount Per Security: $0.3
Board Change • Mar 06No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Secretary & Director Hung Pau is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
